Gilead Sciences to acquire Immunomedics for $21bn

Gilead Sciences is bolstering its oncology offering acquiring Immunomedics in a deal that values the latter at $21 billion.

The agreement will provide Gilead with Trodelvy (sacituzumab govitecan-hziy), a first-in-class Trop-2 directed antibody-drug conjugate (ADC) that was granted accelerated approval by FDA in April for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease.

Immunomedics plans to submit a supplemental Biologics License Application (BLA) to support full approval of Trodelvy in the US in the fourth quarter of 2020 (when the deal is anticipated to close). Immunomedics is also on track to file for regulatory approval in Europe in the first half of 2021.

Beyond mTNBC, Trodelvy is also being studied in an ongoing Phase 3 trial in third line HR+/HER2- breast cancer and a registrational Phase 2 study in bladder cancer.

Additional ongoing studies are evaluating the potential of Trodelvy as a treatment for non-small cell lung cancer and other solid tumour types.

Trodelvy is being studied as both a monotherapy and in combination with checkpoint inhibitors and other non-immuno-oncology products by Immunomedics and independent investigators.

“This acquisition represents significant progress in Gilead’s work to build a strong and diverse oncology portfolio,” said Daniel O’Day, Chairman and CEO of Gilead Sciences

“Trodelvy is an approved, transformational medicine for a form of cancer that is particularly challenging to treat. We will now continue to explore its potential to treat many other types of cancer, both as a monotherapy and in combination with other treatments.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

4D pharma merges with SPAC in $37.6m deal

4D pharma, the listed Leeds-headquartered pharmaceutical company, has merged with Longevity, a special purpose acquisition company (SPAC), in a deal worth up to $37.6...

Cyted acquires Pathognomics Ltd to support expansion of digital pathology and diagnostic reporting services

Cyted Ltd, a developer and provider of artificial intelligence technology and digital diagnostic infrastructure to enable earlier detection of disease, has acquired Pathognomics Limited,...

Record quarter for UK biotech as £1bn is raised

UK biotech companies raised more than £1 billion in equity finance between June and August 2020, the highest quarter for investments in the sector...

Moderna regains rights to RSV vaccine from Merck

Moderna has regained all rights to the respiratory syncytial virus (RSV) vaccine (mRNA-1172) from Merck, including rights to develop RSV vaccines for adult populations. mRNA-1172,...

Takeda & Arrowhead to co-develop RNAi therapy for AATLD

Takeda and Arrowhead Pharmaceuticals will collaborate to develop ARO-AAT, a Phase 2 investigational RNA interference (RNAi) therapy in development to treat alpha-1 antitrypsin-associated liver...

Related news

CHMP recommends ViiV’s long-acting regimen for HIV

The Committee for Medicinal Products for Human Use (CHMP) has recommended ViiV Healthcare’s Vocabria (cabotegravir injection and tablets) in combination with Rekambys (rilpivirine injection)...

4D pharma merges with SPAC in $37.6m deal

4D pharma, the listed Leeds-headquartered pharmaceutical company, has merged with Longevity, a special purpose acquisition company (SPAC), in a deal worth up to $37.6...

Cyted acquires Pathognomics Ltd to support expansion of digital pathology and diagnostic reporting services

Cyted Ltd, a developer and provider of artificial intelligence technology and digital diagnostic infrastructure to enable earlier detection of disease, has acquired Pathognomics Limited,...

Record quarter for UK biotech as £1bn is raised

UK biotech companies raised more than £1 billion in equity finance between June and August 2020, the highest quarter for investments in the sector...